The FDA's independent advisory committee has voted in favor of full approval of Pfizer's COVID-19 pill, Paxlovid, for the treatment of mild to moderate Covid-19 in adults at high risk for severe disease. The drug, a combination of nirmatrelvir and ritonavir, has been available under emergency use authorization since December 2021 and has been used by over 8 million people in the US. The FDA is expected to make a decision on full approval of the drug in the coming weeks.
